News | February 28, 2023
Sanofi reaffirms commitment to rare diseases in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
Subscribe To Our Newsletter & Stay Updated
